Pamrevlumab of little benefit in idiopathic pulmonary fibrosis
31 May 2024
The monoclonal antibody pamrevlumab does not appear to improve outcomes for patients with idiopathic pulmonary fibrosis when compared with placebo, according to the phase III ZEPHYRUS-1 trial.
Debunking the myths about DPP-4 inhibitors
01 May 2024;
Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.